← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › SULFONAMIDES AND TRIMETHOPRIM › Trimethoprim and derivatives
iclaprim
J01EA03
Forms & Strengths
- iclaprim 240mg and 320mg tablets
- iclaprim 10% solution for injection
Adult Dosing
- 240-320mg iv every 12 hours
- treatment duration 5-14 days for complicated skin infections
- treatment duration 7-14 days for hospital-acquired bacterial pneumonia
Pediatric Dosing
- not established in children
- safety and efficacy in pediatric patients have not been established
Indications
- treatment of complicated skin and skin structure infections
- treatment of hospital-acquired bacterial pneumonia
Mechanism of Action
- inhibits bacterial dihydrofolate reductase
- prevents synthesis of tetrahydrofolic acid
Contraindications
- hypersensitivity to iclaprim
- concomitant use with trimethoprim-sulfamethoxazole
Adverse Reactions
- infusion-related reactions
- gastrointestinal adverse effects
- hepatic enzyme elevations
- hypersensitivity reactions
Drug Interactions
- concomitant use with folate or folinic acid may decrease iclaprim efficacy
- increased risk of methotrexate toxicity with concomitant use
- may interact with P-gp inhibitors or inducers
Curated Content: Needs Vetting Before Put to Clinical Use